Short Interest in BrainsWay Ltd. (NASDAQ:BWAY) Increases By 5.3%

BrainsWay Ltd. (NASDAQ:BWAY) was the recipient of a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 41,400 shares, an increase of 5.3% from the July 15th total of 39,300 shares. Based on an average trading volume of 70,000 shares, the short-interest ratio is presently 0.6 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BWAY. Rhumbline Advisers grew its holdings in shares of BrainsWay by 10.3% in the second quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after acquiring an additional 1,695 shares in the last quarter. Tucker Asset Management LLC increased its position in BrainsWay by 1,686.9% in the fourth quarter. Tucker Asset Management LLC now owns 5,450 shares of the company’s stock worth $35,000 after buying an additional 5,145 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of BrainsWay in the fourth quarter valued at $70,000. Virtu Financial LLC bought a new position in shares of BrainsWay during the 1st quarter worth $60,000. Finally, Perritt Capital Management Inc purchased a new stake in BrainsWay in the 2nd quarter worth about $121,000. 30.11% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BWAY. HC Wainwright lifted their target price on BrainsWay from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Oppenheimer boosted their target price on BrainsWay from $10.00 to $11.00 and gave the company an “outperform” rating in a research report on Thursday, May 9th. Finally, Northland Securities increased their price target on BrainsWay from $9.00 to $11.00 and gave the stock an “outperform” rating in a report on Wednesday, August 7th.

BrainsWay Price Performance

BWAY opened at $7.87 on Monday. The firm has a market capitalization of $131.15 million, a PE ratio of -87.44 and a beta of 1.24. BrainsWay has a fifty-two week low of $2.94 and a fifty-two week high of $8.28. The company’s 50-day moving average is $6.62 and its 200 day moving average is $6.07.

BrainsWay (NASDAQ:BWAY) last announced its earnings results on Tuesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter. The company had revenue of $10.01 million for the quarter, compared to analysts’ expectations of $9.40 million. BrainsWay had a negative return on equity of 3.98% and a negative net margin of 4.83%. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. As a group, analysts expect that BrainsWay will post 0.02 EPS for the current year.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.